The FDA grants Fast Track designation to sonelokimab for moderate to severe palmoplantar pustulosis, a chronic inflammatory skin disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results